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Glomerulonephritis and malignancy: A population-based analysis. lesions. This study concerns de novo malignancies after
Background. An association between glomerulonephritis and affirmed glomerular diseases. In Denmark, all kidney bi-
malignant tumors has previously both been found and discarded opsies have been registered since 1985 in a central data-in clinical series, but to our knowledge never has been tested
base. Linkage with the Danish Cancer Registry, in exis-in a population-based setting.
tence since 1943, was performed to analyze for a possibleMethods. The Danish Kidney Biopsy Registry includes all
kidney biopsies performed from 1985. Using a unique personal excess cancer rate after diagnosed GN. Our study identi-
identification number, each person in the registry to the Na- fied cancer cases in the same way as the underlying rates
tional Population Registry and the Danish Cancer Registry were
to avoid major ascertainment bias such as that seen inlinked. Cancer occurrence after the biopsy was compared in
clinical series with an extensive follow-up. Based uponpatients with morphological, glomerular diseases with that of
the general Danish population, taking into account sex, age, the findings, we discuss explanations for a possible associ-
calendar period and time since biopsy, and the 95% confidence ation between glomerulonephritis and malignant tumors.
interval (95% CI) for the observed-to-expected rates was calcu-
lated, assuming a Poisson distribution. Cancer occurrence was
stratified to 1 year, 1 to 4, and 5 years after a biopsy. METHODS
Results. A total of 102 de novo cancers were found in 1958
Glomerular diseases are treated in specialized depart-patients. These cancers represent a two- to threefold excess of
the expected number at 1 and 1 to 4, but not 5 years after ments for nephrology in Denmark. The Danish Kidney
a biopsy. Non-Hodgkin’s lymphomas were observed six to eight Biopsy Registry includes all kidney biopsies performed
times more than expected. Cancer excess was seen in glomeru-
in Denmark from 1985 to the present. The registry datalonephritides with a known or suspected virus etiology.
include: the patient’s personal identification number, dateConclusions. The excess cancer rate could be the result of
underlying undiagnosed tumors whose antigens have initiated of biopsy, up to four diagnoses of morphology using
glomerulonephritis, or the immunosuppressive therapy that the WHO classification, results of immunohistology and
initiated or energized tumor cells. Based on the findings in our electron microscopy, and clinical systemic disease and
study, there is some support for an association to persistent
etiology, if known. Our current study was based on theviruses causing first the glomerulonephritides and then the
light microscopy diagnoses. While some disease entitiesmalignancies, perhaps through a common pathogenesis. This
calls for other studies to be done that are specifically designed such as interstitial nephritis, vascular diseases, diabetes
to investigate this issue, with more data on patient characteris- mellitus and hereditary kidney diseases are not systemat-
tics and confounders. ically biopsied, glomerular diseases are biopsied, ac-
cording to consensus criteria. These biopsies were evalu-
ated by investigators trained in interpretation of renal
An association between glomerulonephritis (GN) and biopsies. The reproducibility of the glomerular diagnosis
malignant tumors previously has been found and dis- (light microscopy) after the WHO classification has been
carded in clinical series, but to our knowledge has not analyzed with kappa statistics and found acceptable with
been tested in a population-based setting [1, 2]. A cancer a kappa value of 0.61 [3]. The biopsies were performed
may be evident before, discovered concomitantly with, most often before a possible subsequent immunosup-
or detected well after the development of glomerular
pressive therapy. De novo or recurrent GN in a trans-
planted kidney was excluded.
After the WHO classification, the GN was divided intoKey words: kidney biopsy, glomerulonephritis, cancer, virus, non-Hodg-
kin’s lymphoma; cyclin-dependent kinases. the following categories: idiopathic/post-infectious (pri-
mary) GN, which is minimal change GN; focal, segmental
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proliferative GN; focal, segmental GN; diffuse membra-and in revised form April 29, 2002
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Table 1. Observed, expected and observed/expected rate of 102 de novo cancers after glomerulonephritis
Years Males Females
after
entry PYRS Obs Exp O/E CI low CI high PYRS Obs Exp O/E CI low CI high
1 1073 17 7.08 2.4 1.4 3.84 693 10 3.48 2.87 1.37 5.35
1–4 2857 36 18.3 1.97 1.38 2.72 1836 17 9.49 1.79 1.04 2.89
5 1508 16 10.37 1.54 0.88 2.5 1145 6 6.41 0.94 0.34 2.06
Total 5438 69 35.75 1.93 1.5 2.44 3674 33 19.39 1.7 1.17 2.39
Abbreviations are: PYRS, person-years; obs, observed; exp, expected; CI, 95% confidence interval (low-high).
diffuse extracapillary GN; diffuse sclerosing GN; and un- Excess cancers were found in the colon (women), lung
and skin (men), and lymphatic tissue in both men andclassified GN. We concentrated on patients with morpho-
logically-defined glomerular diseases, and used the first women (Table 2). Non-Hodgkin lymphomas were in ex-
cess (N  9; 6.6- to 7.4-fold) in both men and women,diagnosis in those cases where several biopsies existed.
The Danish Cancer Registry began operations in 1943, and so was Hodgkin’s disease and myeloma in women
and leukemia in men.covering all cancers in Denmark (2001 population, 5.2
million). The registry has a proven high completeness The glomerular diseases were subdivided after WHO
classification into subgroups as shown in Table 3. Signifi-and validity in the range of 95 to 97% [4]. All cancers in
a person are on record and linked to the unique personal cant excess cancers (1.7- to 4.1-fold) are seen in endocap-
illary, membranous and mesangioproliferative GN inidentification number introduced in 1968 and used exten-
sively in society. men and minor change GN in women. A significant ex-
cess of cancers in lymphatic and hematopoietic tissueBy the unique personal identification number, each
person in the Danish Kidney Biopsy Registry was linked (4.3- to 6.3-fold) was observed in both men and women
(Table 4), and excess could be found in minor change,to the National Population Registry and the Danish Can-
cer Registry, and cancer incidence in the cohort was endocapillary, membranous and mesangioproliferative
GN, however, the numbers here are small.made available up to the end of 1996, when 2550 kidney-
biopsied patients were on file.
The cancer occurrence in patients with morphological,
DISCUSSION
glomerular diseases were compared with that of the gen-
Studies of a possible excess cancer rate in patientseral Danish population, taking into account sex, age, cal-
with GN can be biased in several ways, including selec-endar period and time since biopsy, and the 95% confi-
tion criteria for reference of patients to specialized de-dence interval (95% CI) for the observed-to-expected rates
partments, criteria for diagnosis, and the availability ofwas calculated, assuming a Poisson distribution. Person-
a relevant cancer registry for comparative analyses.years at risk and cancer occurrence data were assessed
We have tried to avoid this by a population-basedfrom date of a biopsy until death, transplantation or end
approach. Denmark has a very specialized hospital sys-of follow-up (Dec. 31, 1996), whichever came first. Patients
tem and patients with kidney diseases are routinely re-with a diagnosis of malignancy before the biopsy were
ferred to departments of nephrology. A consensus existsexcluded. Cancer occurrence was stratified to 0 to1 year,
on indications for kidney biopsies, and these are per-1 to 4, and 5 years after a biopsy to elucidate the effect
formed if glomerular diseases are suspected.of immunosuppressive therapy, if given, and to clarify
One may speculate if GN could be a first symptom ofthat a possible excess cancer rate was not observed only
a silent cancer and hence give spurious results. Such ain the period immediately following the kidney biopsy
mechanism, however, is unlikely since the cancers foundas a sign of undetected cancers at the time of biopsy.
are not known as slow growing, and the excess seen in our
current study is obvious years after the biopsy leading to
RESULTS a diagnosis of GN. Also, the thorough clinical work-up
of the kidney patients speaks against such a relationship.All patients with a glomerular disease were identified.
They comprised 1958 persons (1190 males and 768 fe- Lymphatic infiltrations in the kidneys, such as seen in
non-Hodgkin’s lymphomas (NHL), will not be missed bymales) accruing 9112 person-years (5438 for males and
3674 for females). In this group 102 cancers were de- the pathologists, and hence such cases would be excluded
from our material.tected (69 in males and 33 in females; Table 1). In both
men and women significant excesses of malignancies (2.4 An analysis of a Danish cohort of patients with end-
stage renal diseases, of which some were treated exclu-to 3.5-fold) were found at 1 and 1 to 4 years, however,
not for five years or more after diagnosis. sively with dialysis and some were later transplanted,
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Table 2. Excess cancers were found in the colon (women), lung and skin (men) and lymphatic tissue in both men and women
Males Females
Cancer diagnosis obs exp O/E CI low CI high obs exp O/E CI low CI high
153. Colon, incl recto-sigmoid 4 2.5165 1.59 0.43 4.07 5 1.354 3.69 1.19 8.62
162.0,1 Lung primary, trachea 14 6.0299 2.32 1.27 3.9 1 1.7291 0.58 0.01 3.22
191 Other skin (than melanomas) 17 5.9243 2.87 1.67 4.59 5 2.9087 1.72 0.55 4.01
198-199 Secondary and unspecified sites 3 0.9951 3.01 0.61 8.81 3 0.5556 5.4 1.09 15.78
200-205 Lymphatic and hemopoietic tissue 15 2.3848 6.29 3.52 10.37 9 0.9651 9.33 4.26 17.7
200, 202 Non-Hodgkin lymphoma 6 0.9096 6.6 2.41 14.36 3 0.4036 7.43 1.49 21.72
201 Hodgkin’s disease 1 0.1717 5.82 0.08 32.41 3 0.0747 40.18 8.08 117.4
203 Multiple myoloma 1 0.4038 2.48 0.03 13.78 2 0.1591 12.57 1.41 45.38
204 Leukemia 7 0.8746 8 3.21 16.49 1 0.322 3.11 0.04 17.28
Numbers heading the cancer diagnosis are from the International Classification of Disease. Bold script indicates significant excess. Abbreviations are: obs, observed;
exp, expected; CI, 95% confidence interval (low-high).
Table 3. Cancers in relation to the glomerular diseases subdivided into subgroups after WHO classification
Males Females
140–205 All malignant neoplasms obs exp O/E CI low CI high obs exp O/E CI low CI high
1 Minor change 3 1.2679 2.37 0.48 6.91 5 1.2287 4.07 1.31 9.5
2 Focal segm. prolif. 8 4.7391 1.69 0.73 3.33 1 2.4635 0.41 0.01 2.26
3 Focal segmental sclerosis 4 1.4343 2.79 0.75 7.14 1 0.3806 2.63 0.03 14.62
4 Membranoproliferative 2 1.5874 1.26 0.14 4.55 2 1.257 1.59 0.18 5.74
5 Extracapillary 10 5.4802 1.82 0.87 3.36 5 2.3432 2.13 0.69 4.98
6 Endocapillary 4 1.0128 3.95 1.06 10.11 1 0.4963 2.02 0.03 11.21
7 Diffuse membranous 13 7.28 1.79 0.95 3.05 7 3.5455 1.97 0.79 4.07
8 Diffuse mesangial proliferative 13 7.1 1.83 0.97 3.13 8 4.5713 1.75 0.75 3.45
9 Diffuse sclerosis 3 1.5139 1.98 0.4 5.79 — 0.5198 — — 5.76
10 Unclassified 9 4.3373 2.08 0.95 3.94 3 2.5837 1.16 0.23 3.39
Total 69 35.753 1.93 1.5 2.44 33 19.3897 1.7 1.17 2.39
Bold script indicates significant excess. Abbreviations are: obs, observed; exp, expected; CI, 95% confidence interval (low-high).
Table 4. Excess cancers in lymphatic tissue in relation to the glomerular diseases subdivided in subgroups after WHO
Males Females
200–205 Lymphatic and
hemopoietic tissue obs exp O/E CI low CI high obs exp O/E CI low CI high
1 Minor change 2 0.1035 19.32 2.17 69.74 2 0.0677 29.55 3.32 106.7
6 Endocapillar 2 0.07 28.72 3.23 103.7 — 0.0259 — — 115.6
7 Diffuse membranous 4 0.4644 8.61 2.32 22.05 — 0.1692 — — 17.7
8 Diffuse mesangial proliferative 2 0.5122 3.9 0.44 14.1 4 0.2374 16.85 4.53 43.14
Total (all groups) 15 2.3848 6.29 3.52 10.37 9 0.9651 9.33 4.26 17.7
Bold script indicates significant excess. Abbreviations are; obs, observed; exp, expected; CI, 95% confidence interval (low-high).
showed that excess cancer risk in such patients occurred both circumstances. At the time of biopsy immunosup-
pressive therapies normally are not given.after transplantation and not during dialysis [5].
Since not all patients with kidney diseases proceed to Glomerulonephritis may be primary, restricted in clin-
ical manifestations to the kidney, or it may be part of aterminal uremia with the possibility for renal replace-
ment therapy, we found it of interest to analyze a cohort multi-system disease, most frequently systemic lupus or
vasculitis. The etiologies in most GN are still unknown,of patients with biopsy-verified kidney diseases who were
followed from the day of biopsy, that is, from an early however, much evidence now suggests that infectious
agents such as bacteria or virus induce GN by triggeringphase. We focused on glomerular diseases, since they
are systematically biopsied and most develop as a result an autoimmune response, leading to the formation of
immune complex deposits in glomeruli, or evoke a cell-of immune dysregulation, either an inappropriate im-
mune response to self-antigens occurring through a fail- mediated immune response to antigens in or of the glo-
merulus [reviewed in 10].ure of tolerance (autoimmunity) or an ineffectual re-
sponse to a foreign antigen. Viruses may play a role in We found an overall significant excess of malignancies
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in both men and women for the entire group of GN The virus must be able to infect host cells without killing
them. There must be mechanisms for maintaining thepatients. The excess was found in both the 1 and 1 to
4 year groups, however, not in the 5 year group, after viral genome in host cells. Finally, the virus must avoid
detection and elimination by the host’s immune system.diagnosis. This could be taken as an argument against a
long-term effect of immunosuppression; however, our Viruses that persist in humans include cytomegalovirus
(CMV), Epstein-Barr virus (EBV), hepatitis B (HBV)study did not allow a further analysis of the possible
influence of immunosuppression. The absence of an in- and -C (HCV) viruses, human papilloma virus (HPV),
parvovirus B19, human immune deficiency virus (HIV)creased risk after five years is probably due to the sample
size, but could be taken as an argument against an associ- and polyoma virus. Most of these are known to be able
to cause cancer in immune deficient patients [7], but someation between glomerulonephritis and malignancy. How-
ever, if a virus etiology causes first the glomerulonephri- (EBV, HBV, HCV, parvovirus B19, HIV) are known also
to be able to cause GN, and still more nephritogenic/tis and then the malignancy, this would be seen in the
first years and not so much in the long run, as learned oncogenic viruses doubtless remain to be detected.
Hepatitis B virus, especially in its chronic form, canfrom the literature on malignancy after organ trans-
plantation, especially concerning the non-Hodgkin lym- cause GN and polyarteritis nodosa [8]. The GN is often
membranous (5% of adults are HBV associated), butphomas.
The excess was mostly seen in sites where a virus eti- membranoproliferative GN, mesangioproliferative GN
and even IgA and minimal change GN also can be seen.ology was suspected, and consequently such an effect may
be emphasized further by immunosuppression. Most evi- HCV is often associated with a cryoglobulinemic mem-
branoproliferative GN, however, mesangioproliferativedent was the cancer excess in lymphatic and hemato-
poietic tissue with observed/expected (O/E) rates of six and membranous GN forms can be seen [reviewed in 9].
This etiology is underlined by the occurrence of a deto nine in men and women. This corresponds very well to
findings after transplantation where viruses from the novo membranoproliferative GN in HCV infected kid-
ney transplanted patients [10].herpes group have been suspected culprits.
If divided into morphological subgroups of GN, the Viruses from the herpes group also have been postu-
lated as causing GN. Those are CMV linked to membra-numbers of malignancies are small. From the earlier
kappa-statistical study performed in the same cohort as noproliferative GN [11], EBV linked to IgA GN, mem-
branous GN, minimal change GN, focal sclerosing GNanalyzed in our current study [3] we know that reproduc-
ibility between different observers varied between cres- and immune complex-mediated GN [12].
Epstein-Barr virus has been linked to non-Hodgkincentic (0.81) to membranoproliferative (0.40) GN, which
could be the reason for not finding more subgroup- lymphomas [13, 14] and the same has been disputed for
HCV [reviewed in 15]. Furthermore, EBV persistencespecific cancer excess. Another point is the timing of a
biopsy, since many glomerulonephritides over time change seems to be associated with a far greater spectrum of
malignancies than previously anticipated [13, 14].from one category to another and, furthermore, many
have one or more different morphological components. For some tumors, such as gastric mucosa-associated
lymphoid tissue (MALT) lymphoma and non-HodgkinOn the other hand, the study comprises 1958 persons
with 100 to 200 in each group, making it the biggest ever lymphoma after bone marrow transplantation and organ
transplantation, tumor regression has been observedperformed, so the reason also could be that excess cancer
in GN is not so much linked to specific morphological when the infection was treated [16] and/or the immuno-
suppression was decreased or ceased. Similar observa-subgroups (membranous GN has often been mentioned,
based on the findings of four cancers among 107 membra- tions have been made in cases of CMV [17], HBV [18]
and HCV-induced GN [19] and lymphoma [20].nous GN [2]) as to the glomerular disease per se. In any
case, it is noteworthy that minimal change, endocapillary, Recurrence of GN after transplantation has been eval-
uated in an extensive series [21] with rates for histologic/membranous, and mesangial proliferative GN show ex-
cess cancers in lymphatic tissue (Tables 3 and 4). clinical recurrence on 25/25% for membranous GN, 25/
12.5% for membranoproliferative GN type I, and 85/5%A common virus etiology for both the glomerular dis-
ease and the malignancies could be due either to an onco- for type II. There are also reports of the repetitive recur-
rence of membranous GN in successive transplants [22].genic effect of the viruses per se or a disturbed clearance
of biological mediators of importance for both virus ef- It is striking that those GN that recur under the extensive
post-transplant immunosuppressive regime are the samefects and oncogenesis, which are normally cleared in the
glomeruli. In this aspect it is important that the glomeruli as those where the effect of that therapy is most disputed
when they occur in the native kidneys, and it can behave a special position in the body, inasmuch as the
kidneys receive 25% of the cardiac output. speculated that the culprit is not so much the immuno-
logic feature of GN as an underlying cause, which veryWithin an infected host viruses can establish long-term
persistence. Three general conditions must be fulfilled. well may be a virus. Along this line of thought, it is
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noteworthy that most recurrences are seen in GN of mors whose antigens have initiated glomerulonephritis,
or the result of immunosuppressive therapy that initiatedknown or suspected virus etiology. This theory is further
emphasized by the findings of resolution by antiviral or energized tumor cells. Based on our findings, there
drugs of some, but not all, of the GN caused by CMV is some support for a virus etiology, with the hypothesis
[17] using ganciclovir and HBV [23] and HCV [24] by that infections with persistent viruses of the herpes and
-interferon (alone or combined with ribavirin), which hepatitis groups first caused the glomerulonephritides
has been found to be effective even in some cases of post- and then the malignancies. This could be through a com-
transplant lymphoproliferative disease (PTLD) [17, 20]. mon pathogenesis of disturbed cyclin kinase/inhibitor
Reports on the resolution of hepatitis B [25] and -C [26] balance. This hypothesis calls for other studies to be
virus-related membranoproliferative glomerulonephritis done that are specifically designed to investigate this
after orthotopic liver transplantation is in agreement issue, and that will utilize more data on patient character-
with this theory. istics and confounders.
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